Craif Secures $22M to Revolutionize Early Cancer Detection with AI-Powered miRNA Tech
Japanese startup Craif is making waves as it secures $22 million in Series C funding to bring its groundbreaking AI-driven cancer detection platform to the U.S. market. Using microRNA (miRNA) from urine, Craif's miSignal test offers a non-invasive alternative to traditional methods, aiming to detect seven types of cancer early on. With plans to expand detection capabilities and explore other applications, this innovative platform is on track for U.S. trials by 2029, with FDA approval on the horizon.
Apr 28